key: cord-0775783-iw3wv973
authors: Edara, Venkata-Viswanadh; Manning, Kelly E.; Ellis, Madison; Lai, Lilin; Moore, Kathryn M.; Foster, Stephanie L.; Floyd, Katharine; Davis-Gardner, Meredith E.; Mantus, Grace; Nyhoff, Lindsay E.; Bechnak, Sarah; Alaaeddine, Ghina; Naji, Amal; Samaha, Hady; Lee, Matthew; Bristow, Laurel; Hussaini, Laila; Ciric, Caroline Rose; Nguyen, Phuong-Vi; Gagne, Matthew; Roberts-Torres, Jesmine; Henry, Amy R.; Godbole, Sucheta; Grakoui, Arash; Sexton, Marybeth; Piantadosi, Anne; Waggoner, Jesse J.; Douek, Daniel C.; Anderson, Evan J.; Rouphael, Nadine; Wrammert, Jens; Suthar, Mehul S.
title: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant
date: 2021-12-22
journal: bioRxiv
DOI: 10.1101/2021.12.20.473557
sha: bcf25b860f6b0143a95de3eed98be996bb8f44bc
doc_id: 775783
cord_uid: iw3wv973

The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike protein, the principal antigenic target of these vaccines, has raised concerns over the neutralizing activity of vaccine-induced antibody responses. The Omicron variant, which emerged in November 2021, consists of over 30 mutations within the spike protein. Here, we used an authentic live virus neutralization assay to examine the neutralizing activity of the SARS-CoV-2 Omicron variant against mRNA vaccine-induced antibody responses. Following the 2nd dose, we observed a 30-fold reduction in neutralizing activity against the omicron variant. Through six months after the 2nd dose, none of the sera from naïve vaccinated subjects showed neutralizing activity against the Omicron variant. In contrast, recovered vaccinated individuals showed a 22-fold reduction with more than half of the subjects retaining neutralizing antibody responses. Following a booster shot (3rd dose), we observed a 14-fold reduction in neutralizing activity against the omicron variant and over 90% of boosted subjects showed neutralizing activity against the omicron variant. These findings show that a 3rd dose is required to provide robust neutralizing antibody responses against the Omicron variant.

The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent 25 neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 26

However, the global emergence of SARS-CoV-2 variants with mutations in the spike protein, the 27 principal antigenic target of these vaccines, has raised concerns over the neutralizing activity of with more than half of the subjects retaining neutralizing antibody responses. Following a booster 36 shot (3rd dose), we observed a 14-fold reduction in neutralizing activity against the omicron 37 variant and over 90% of boosted subjects showed neutralizing activity against the omicron variant. 38

These findings show that a 3rd dose is required to provide robust neutralizing antibody responses 39 against the Omicron variant.

The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent and  42   durable neutralizing antibody responses against the severe acute respiratory syndrome  43 coronavirus 2 (SARS-CoV-2) 1-3 . The global emergence of SARS-CoV-2 variants with mutations 44 in the spike protein, the principal antigenic target of these vaccines, has raised concern regarding 45 the effectiveness of these vaccines. We previously found that mRNA vaccine-induced antibody fold and 30-fold reduction as compared to WA1, respectively (Fig. 1a) . Further, only 21% of the 73 subjects showed neutralizing antibody titers against the B.1.1.529 variant. 74 75 Next, we examined the durability of neutralizing antibody responses in vaccinated subjects 6 76 months after receiving the 2nd dose. This cohort was divided between individuals with no known 77 prior COVID-19 exposure and those that had recovered from COVID-19 and then received the 78

Moderna or Pfizer-BioNTech vaccine. In naïve vaccinated subjects, the GMTs at 6 months were 79 53 for WA1, 23 for B.1.351, and <20 for B.1.1.529 (Fig. 1b) . This corresponded to a 2.3-fold 80 reduction against B.1.351 as compared to WA1, however, none of these subjects showed any 81 detectable neutralizing activity against the B.1.1.529 variant. In recovered individuals that 82 received the vaccine, the GMTs were 719 for WA1, 366 for B.1.351 and 33 for B.1.1.529 and 83 corresponded to a 2-and 22-fold reduction as compared to WA1, respectively (Fig. 1c) Sampling occurred 1-4 weeks after the booster dose. Across all subjects that received a booster 93 dose (Fig. 1d) Limitations of this study include: 1) small sample size; 2) selection bias in sampling for the 3rd 105 dose (Pfizer-BioNTech 3rd dose received EUA approval prior to Moderna); 3) this study was a 106 cross-sectional analysis of subjects that received either the primary or booster mRNA vaccines; 107 4) we are not able to link the clinical outcomes with the neutralization findings; 5) we cannot 108 exclude that some of the naïve individuals were exposed to COVID-19 but were asymptomatic; 109 and 6) this study did not evaluate T cell immunity which likely plays a role in protection against 110 COVID-19. 111 Figure 1. Neutralization antibody responses against WA1/2020, B.1.351, and B.1.1.529  113 Each specimen was tested in duplicate. The FRNT-50 titers were interpolated using a 4-193 parameter nonlinear regression in GraphPad Prism 9.2.0. Samples that do not neutralize at the 194 limit of detection at 50% are plotted at 10 and was used for geometric mean and fold-change 195 calculations.

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of 198 Blinded Phase

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Durability of mRNA-1273 vaccine-induced antibodies against SARS-204 CoV-2 variants

Durability of immune responses to the BNT162b2 mRNA vaccine

Infection-and vaccine-induced antibody binding and neutralization of 208 the B.1.351 SARS-CoV-2 variant

Infection and Vaccine-Induced Neutralizing-Antibody Responses to 210 the SARS-CoV-2 B.1.617 Variants

Development of a Rapid Focus Reduction Neutralization Test 212 Assay for Measuring SARS-CoV-2 Neutralizing Antibodies

An Infectious cDNA Clone of SARS-CoV-2

Viridot: An automated virus plaque (immunofocus) counter for the 217 measurement of serological neutralizing responses with application to dengue virus

Viruses and cells. VeroE6-TMPRSS2 cells were generated and cultured as previously 148 described 7 . nCoV/USA_WA1/2020 (WA/1), closely resembling the original Wuhan strain and 149 resembles the spike used in the mRNA-1273 and Pfizer-BioNTech vaccine, was propagated from 150 an infectious SARS-CoV-2 clone as previously described 9 . icSARS-CoV-2 was passaged once to 151 generate a working stock.